deltatrials
Completed PHASE3 NCT00597753

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

AFX01-12: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin Alfa

Sponsor: Affymax

Conditions Anemia Chronic Kidney Disease Chronic Renal Failure
Interventions Epoetin Alfa peginesatide
Updated 7 times since 2017 Last updated: Feb 6, 2013 Started: Sep 30, 2007 Primary completion: Jul 31, 2009 Completion: Jan 31, 2010

This PHASE3 trial investigates Anemia and Chronic Kidney Disease and is currently completed. Affymax leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Affymax
  • Takeda
Data source: Affymax

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States, Allentown, United States, Appleton, United States, Arlington, United States, Augusta, United States, Baton Rouge, United States, Bethesda, United States, Boise, United States, Brooklyn, United States, Canton, United States and 68 more location s